睡眠不佳是癌症的常见副作用。大麻越来越多地用于控制癌症治疗相关症状，包括睡眠。本研究调查了加拿大癌症幸存者使用大麻睡眠的相关因素。通过安格斯·里德研究所招募了加拿大成年癌症幸存者 (N = 940)，并完成了一项在线横断面调查。单变量和多元二项逻辑回归模型确定了与使用大麻睡眠相关的因素。 在参与者中（法师 = 64.5 岁；女性 = 51.1%；白人= 92.9%），25.1%（n = 236）目前使用大麻入睡。如果参与者被确定为男性或女性以外的性别 (AOR = 11.132)、被诊断患有多种医疗状况 (2:AOR = 1.988; 3 :AOR = 1.902)、两种心理状况，则他们使用大麻入睡的可能性更大(AOR = 2.171)、多种睡眠障碍(AOR = 2.338)、失眠(AOR = 1.942)、骨骼(AOR = 6.535)、胃肠道(AOR = 4.307)、泌尿生殖系统(AOR = 2.586)、血液学(AOR = 2.586) = 4.739),或未列出的癌症（AOR = 3.470）、仅接受激素治疗（AOR = 3.054）、大量饮酒（AOR = 2.748）或有轻度失眠（AOR = 1.828）。年龄较大的参与者 (AOR=.972) 和患有睡眠呼吸暂停的人不太可能使用大麻入睡 (AOR=.560)。鉴于大麻的流行程度，需要研究了解与加拿大癌症中使用大麻作为睡眠辅助剂相关的因素幸存者可能会影响其使用和有效性，以及这些因素是否成为获得循证治疗的障碍。

Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors.Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep.Of the participants (Mage = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560).Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.